Cargando…

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in colorectal cancer. We have established an extended RAS and BRAF mutation assay using a next-generation sequencer to analyze these mutations. Multiplexed deep sequencing was performed to detect somati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Kazuko, Tsurutani, Junji, Yamanaka, Takeharu, Yoneshige, Azusa, Ito, Akihiko, Togashi, Yosuke, De Velasco, Marco A., Terashima, Masato, Fujita, Yoshihiko, Tomida, Shuta, Tamura, Takao, Nakagawa, Kazuhiko, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425536/
https://www.ncbi.nlm.nih.gov/pubmed/25954997
http://dx.doi.org/10.1371/journal.pone.0121891
_version_ 1782370500453859328
author Sakai, Kazuko
Tsurutani, Junji
Yamanaka, Takeharu
Yoneshige, Azusa
Ito, Akihiko
Togashi, Yosuke
De Velasco, Marco A.
Terashima, Masato
Fujita, Yoshihiko
Tomida, Shuta
Tamura, Takao
Nakagawa, Kazuhiko
Nishio, Kazuto
author_facet Sakai, Kazuko
Tsurutani, Junji
Yamanaka, Takeharu
Yoneshige, Azusa
Ito, Akihiko
Togashi, Yosuke
De Velasco, Marco A.
Terashima, Masato
Fujita, Yoshihiko
Tomida, Shuta
Tamura, Takao
Nakagawa, Kazuhiko
Nishio, Kazuto
author_sort Sakai, Kazuko
collection PubMed
description Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in colorectal cancer. We have established an extended RAS and BRAF mutation assay using a next-generation sequencer to analyze these mutations. Multiplexed deep sequencing was performed to detect somatic mutations within KRAS, NRAS, and BRAF, including minor mutated components. We first validated the technical performance of the multiplexed deep sequencing using 10 normal DNA and 20 formalin-fixed, paraffin-embedded (FFPE) tumor samples. To demonstrate the potential clinical utility of our assay, we profiled 100 FFPE tumor samples and 15 plasma samples obtained from colorectal cancer patients. We used a variant calling approach based on a Poisson distribution. The distribution of the mutation-positive population was hypothesized to follow a Poisson distribution, and a mutation-positive status was defined as a value greater than the significance level of the error rate (α = 2 x 10(-5)). The cut-off value was determined to be the average error rate plus 7 standard deviations. Mutation analysis of 100 clinical FFPE tumor specimens was performed without any invalid cases. Mutations were detected at a frequency of 59% (59/100). KRAS mutation concordance between this assay and Scorpion-ARMS was 92% (92/100). DNA obtained from 15 plasma samples was also analyzed. KRAS and BRAF mutations were identified in both the plasma and tissue samples of 6 patients. The genetic screening assay using next-generation sequencer was validated for the detection of clinically relevant RAS and BRAF mutations using FFPE and liquid samples.
format Online
Article
Text
id pubmed-4425536
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44255362015-05-21 Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing Sakai, Kazuko Tsurutani, Junji Yamanaka, Takeharu Yoneshige, Azusa Ito, Akihiko Togashi, Yosuke De Velasco, Marco A. Terashima, Masato Fujita, Yoshihiko Tomida, Shuta Tamura, Takao Nakagawa, Kazuhiko Nishio, Kazuto PLoS One Research Article Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in colorectal cancer. We have established an extended RAS and BRAF mutation assay using a next-generation sequencer to analyze these mutations. Multiplexed deep sequencing was performed to detect somatic mutations within KRAS, NRAS, and BRAF, including minor mutated components. We first validated the technical performance of the multiplexed deep sequencing using 10 normal DNA and 20 formalin-fixed, paraffin-embedded (FFPE) tumor samples. To demonstrate the potential clinical utility of our assay, we profiled 100 FFPE tumor samples and 15 plasma samples obtained from colorectal cancer patients. We used a variant calling approach based on a Poisson distribution. The distribution of the mutation-positive population was hypothesized to follow a Poisson distribution, and a mutation-positive status was defined as a value greater than the significance level of the error rate (α = 2 x 10(-5)). The cut-off value was determined to be the average error rate plus 7 standard deviations. Mutation analysis of 100 clinical FFPE tumor specimens was performed without any invalid cases. Mutations were detected at a frequency of 59% (59/100). KRAS mutation concordance between this assay and Scorpion-ARMS was 92% (92/100). DNA obtained from 15 plasma samples was also analyzed. KRAS and BRAF mutations were identified in both the plasma and tissue samples of 6 patients. The genetic screening assay using next-generation sequencer was validated for the detection of clinically relevant RAS and BRAF mutations using FFPE and liquid samples. Public Library of Science 2015-05-08 /pmc/articles/PMC4425536/ /pubmed/25954997 http://dx.doi.org/10.1371/journal.pone.0121891 Text en © 2015 Sakai et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sakai, Kazuko
Tsurutani, Junji
Yamanaka, Takeharu
Yoneshige, Azusa
Ito, Akihiko
Togashi, Yosuke
De Velasco, Marco A.
Terashima, Masato
Fujita, Yoshihiko
Tomida, Shuta
Tamura, Takao
Nakagawa, Kazuhiko
Nishio, Kazuto
Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
title Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
title_full Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
title_fullStr Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
title_full_unstemmed Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
title_short Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
title_sort extended ras and braf mutation analysis using next-generation sequencing
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425536/
https://www.ncbi.nlm.nih.gov/pubmed/25954997
http://dx.doi.org/10.1371/journal.pone.0121891
work_keys_str_mv AT sakaikazuko extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT tsurutanijunji extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT yamanakatakeharu extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT yoneshigeazusa extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT itoakihiko extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT togashiyosuke extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT develascomarcoa extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT terashimamasato extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT fujitayoshihiko extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT tomidashuta extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT tamuratakao extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT nakagawakazuhiko extendedrasandbrafmutationanalysisusingnextgenerationsequencing
AT nishiokazuto extendedrasandbrafmutationanalysisusingnextgenerationsequencing